Cetuximab rechallenge in molecularly selected metastatic colorectal cancer: the randomized CAVE-2 GOIM trial
GastroenterologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- Annals of oncology : official journal of the European Society for Medical Oncology
- Publicado em
- 22 dez 2025
- Citações
- 10
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Cetuximab rechallenge in molecularly selected metastatic colorectal cancer: the randomized CAVE-2 GOIM trial
D Ciardiello, G Martini, L Boscolo Bielo, F Pietrantonio, A Raimondi, P Manca, S Pisconti, C Nisi, G Tortora, L Salvatore et al.
Descritores MeSH
- Colorectal Neoplasms
- Antineoplastic Combined Chemotherapy Protocols
- Cetuximab
- Adult
- Aged
- Aged, 80 and over
- Female
- Humans
- Male
- Middle Aged
Veja também
Estudos relacionados
- Exploring Early Kinetic Profiles of CEA, ctDNA and cfDNA in Patients With RAS-/BRAF-Mutated Metastatic Colorectal Cancer
- Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO
- Clinical Validity of FoundationOne Liquid CDx for Detection of BRAFV600E in Colorectal Cancer
- Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis